Abstract：【Objective】To investigate the efficacy and safety of amphotericin B inhalation in the treatment of HIV/AIDS patients with oral candidiasis. 【Methods】A total of 55 patients with HIV/AIDS and oral candidiasis admitted to Beijing You'an Hospital from June 2017 to June 2018 were enrolled. The amphotericin oxygen inhalation was used to observe the efficacy and adverse reactions. 【Results】The total effective rate of amphotericin B inhalation for treatment of HIV/AIDS with oral candidiasis was 96.4%. The incidence of adverse reaction like cough was 9.0%, and the incidence of nausea was 5.5%. However, both were tolerable. 【Conclusion】Amphotericin B inhalation is safe and effective in the treatment of oral candidiasis in patients with HIV/AIDS, which is worthy of clinical promotion.
[1] 葛风华. HIV/AIDS 患者口腔念珠菌的感染状况和耐药性分析[D].南方医科大学, 2012. [2] Samaranayake LP, Keung Leung W, Jin L. Oral mucosal fungal infections[J].Periodontology,2009, 49(1): 39-59. [3] 毛莉萍, 孟海涛, 钱文斌, 等. 伊曲康唑针剂治疗恶性血液病化疗后深部真菌感染疗效观察[J].中华内科杂志, 2005,44(8):618-619. [4] Shah SP, Misra A. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance[J].Die Pharmazie,2004, 59(10): 812-813. [5] 栾文民. 艾滋病的口腔表征及医护人员的防护[M].北京:人民卫生出版社, 1999. [6] Khongkunthian P, Grote M, Isaratanan W,et al. Oral manifestations in HIV‐positive adults from Northern Thailand[J].J Oral Pathol Med,2001, 30(4): 220-223. [7] Ramirez-Amador V, Esquivel‐Pedraza L, Sierra-Madero J, et al. Oral manifestations of HIV infection by gender and transmission category in Mexico City[J].J Oral Pathol Med,1998, 27(3): 135-140. [8] Oji C, Chukwuneke F. Evaluation and treatment of oral candidiasis in HIV/AIDS patients in Enugu, .Nigeria[J].Oral Maxillofac Surg,2008, 12(2):67-71. [9] Meis JFGM, Verweij PE. Current management of fungal infections[J].Drugs,2001, 61(1): 13-25. [10] Brajtburg J, Powderly W G, Kobayashi G S, et al. Amphotericin B: current understanding of mechanisms of action[J].Antimicrob Agents Chemother,1990, 34(2): 183.
2019, Vol. 36 
